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Abstract  
A loss-of-function variant in the prolactin receptor (PRLR) was previously reported in a 
woman with persistent postpartum galactorrhea; however, this paradoxical phenotype is 
not entirely understood. Here we describe a 35-year-old female who presented with 
idiopathic hyperprolactinemia associated with complete absence of lactation after each of 
her two deliveries. She is a compound heterozygote for loss-of-function variants of PRLR. 
Her unaffected parents are heterozygotes. These findings are consistent with previous 
work showing that mice deficient in functional Prlr do not lactate.  
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Introduction  
Prolactin, a pituitary hormone, plays diverse roles in vertebrates; its known roles in 
human are in processes of lactation and reproduction1,2. A loss-of-function variant in the 
gene encoding the prolactin receptor (PRLR) has been reported in a proband with 
persistent postpartum galactorrhea and hyperprolactinemia3,4. The proband and two her 
sisters were heterozygous for a missense variant (H212R). The proband required 
dopamine agonist therapy to terminate the persistent galactorrhea after all (four) of her 
deliveries. She and a sister were oligomenorrheic; her other sister was infertile. The study3 
of these sisters raises questions. Did the loss-of-function H212R variant cause postpartum 
galactorrhea?2–7 Are infertility and oligomenorrhea the consequences of PRLR mutation 
or coincidental symptoms?6 The phenotype of the proband was not observed in mice 
heterozygous for a knockout allele: Prlr'/+ mice are normoprolactinemic, whereas Prlr
' /'  mice are hyperprolactinemic2,8. Is the allelic regulation of prolactin different 
between mice and humans? Shedding light on some of these questions is our report, here, 
of a female proband carrying biallelic loss-of-function PRLR variants with lactation 
failure associated with hyperprolactinemia. 
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Case presentation 
The proband (Fig. 1) was a 35-year-old woman (gravida 2, para 2; height, 152 cm; weight, 
50 kg). She began menstruating at 12 years of age, and her menstruation became regular 
in 6 months (approximately 28-day intervals). She underwent laparoscopic cystectomy 
for bilateral chocolate cysts at 27 years of age. She got married at 28 years of age and 
sought the help of a gynecologist after a year of not being able to conceive. She was 
diagnosed with hyperprolactinemia (128 ng/mL) but had no galactorrhea. Cabergoline 
was prescribed, but the patient did not take the medication regularly due to nausea, and 
subsequently, her prolactin level was not measured. Pregnancy was achieved after the 
second intrauterine insemination after a single injection of human menopausal 
gonadotropin (150 IU) followed by human chorionic gonadotropin (5,000 IU). An 
ultrasound examination revealed placenta previa. The fetus was large for gestational age 
(+2.9 SD) since 26 weeks of pregnancy. The pregnancy was associated with mild 
polyhydramnios after 28 weeks but was otherwise normal. Oral glucose (75 g) tolerance 
test at 28 weeks of pregnancy revealed normal blood glucose levels (77 mg/dL, 134 
mg/dL, and 104 mg/dL at 0, 60, and 120 min after the ingestion, respectively). The 
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polyhydramnios resolved spontaneously before 36 weeks of gestation. She delivered a 
healthy boy (3766 g, + 2.8 SD) by cesarean section at 37 weeks and 6 days of pregnancy. 
Throughout the postpartum and puerperal period, she experienced neither breast tension 
nor galactorrhea. A chest X-ray (Fig. 2) indicates the contour of the breast taken for the 
preoperative screening at 36 weeks of the first pregnancy. Regular menstrual cycles 
associated with ovulation resumed 14 weeks after the delivery. The proband became 
pregnant at 17 months after the first delivery, without any infertility treatment. Her 
pregnancy was uneventful, and she delivered a healthy girl (3340 g, + 1.5 SD) at 38 weeks 
of pregnancy. Once again, the patient did not experience breast tension or galactorrhea. 
Menstruation associated with ovulation resumed 8 weeks after the second delivery. The 
patient was referred to our hospital for examinations because her prolactin level was 
persistently high (188–255 ng/mL) after the delivery.  
A thyrotropin-releasing hormone loading test revealed a high basal level of prolactin 
together with an excessive response (Fig. 3). Standard screening for larger molecular 
weight-forms of prolactin (macroprolactin) with polyethylene glycol precipitation 
demonstrated that macroprolactin accounted for 29% of the circulating prolactin, which 
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is within the normal range of <40%. Magnetic resonance imaging revealed no evidence 
of a pituitary tumor (Fig. 4). 
Serum electrolyte levels were normal: Na, 140 (normal range: 135–145) mEq/L; K, 5.1 
(3.6–5.0) mEq/L; Cl, 104 (98–108) mEq/L; Ca, 9.6 (8.6–10.1) mg/dL; and IP, 4.6 (2.5–
4.5) mg/dL. The serum level of dehydroepiandrosterone sulfate was 215 (normal range, 
23–266) µg/dL and that of IGF-1 was 119 (normal range, 111– 279) ng/ml. Serum 
hormones were within the normal range, except for prolactin, which was elevated both at 
the early proliferative phase (LH, 4.5 IU/L; FSH, 8.8 IU/L; TSH, 1.07 mIU/ml; estradiol, 
57 pg/ml; and prolactin, 200 ng/ml) and at mid-luteal phase (LH, 3.7 IU/L; FSH, 3.4 
IU/L; estradiol, 82 pg/ml; progesterone, 14.5 ng/ml, testosterone, 0.24 ng/ml; and 
prolactin, 188 ng/ml). Because the patient was once diagnosed with hyperlipidemia by 
medical examination at the age of 30 years (Table 1), we measured serum lipids and 
confirmed hyperlipemia: TG, 88 (35–149) mg/dL; LDL, 193 (<139) mg/dL; and HDL, 
79 (>40) mg/dL. The modest temporal increase in LDL level after the age of 30 years 
suggests constitutional or dietary causes rather than a specific metabolic change caused 
by PRLR variants. 
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The proband’s mother (61 years) was healthy at presentation and reported that she did not 
have and had not previously had menstrual irregularities or infertility. She had breastfed 
each of her three children. She reported that she had been concerned about insufficient 
production of breastmilk and had supplemented breast-feeding with synthetic milk. 
Lactation had ceased spontaneously by the end of the third month of each puerperium. 
The proband’s father (69 years) was also fertile and healthy, except for mild hypertension. 
The serum prolactin levels of the proband’s mother and father were 11 and 12 ng/mL, 
respectively. The proband’s younger sister (25 years) was healthy and 18 weeks pregnant, 
with a prolactin level of 73 ng/mL at presentation. The proband’s younger brother (30 
years) was also healthy with a prolactin level of 9 ng/ml. 
 
Materials and Methods 
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DNA extraction and direct DNA sequencing 
We extracted genomic DNA from 200 µl of a peripheral blood sample using the QIAamp 
DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s 
instructions. Each exon of PRLR was amplified using PrimeSTAR GXL polymerase 
(TaKaRa Bio Inc, Shiga, Japan) and exon-specific primers (Table 2). The PCR products 
were then mixed with ExoSAP-IT reagents (Thermo Fisher Scientific, Waltham, MA, 
USA) and incubated at 37°C for 15 min and then at 80°C for 15 min. Subsequently, the 
clean PCR products were sequenced using the BigDye Terminator v1.1 Cycle Sequencing 
kit (Applied Biosystems, City of Foster City, CA), BigDye X Terminator Purification Kit 
(ABI), and ABI prism 310 Genetic Analyzer (ABI). We used the same primers that were 
used for PCR amplification of genomic DNA. 
PRLR expression vector 
The EF1A-human PRLR-GFP plasmid, in which the full-length prolactin receptor coding 
sequence (NM_000949.6) was subcloned, was purchased from VectorBuilder (Santa 
Clara, CA, USA). The vector has a green fluorescent protein tag at the C terminal of the 
prolactin receptor sequence. A full sequence of the vector is available at 
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https://en.vectorbuilder.com/vector/VB170626-1134dhm.html. We introduced R171Ter, 
P269L and, H212R mutations into the EF1A-human PRLR-GFP plasmid using PCR-
based mutagenesis with the PrimeSTAR MAX DNA polymerase (Takara, Tokyo, Japan). 
Mutagenesis primers are presented in the Table 2. We confirmed the fidelity of the 
constructs by sequencing. 
Cell culture and plasmid transfection 
HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
GlutaMAX (Thermo Fisher Scientific, Waltham, MA) containing 5% fetal bovine serum 
(Eqitech-Bio, Kerrville, TX), 50 U/ml penicillin, and 50 µg/ml streptomycin (Thermo 
Fisher Scientific). 
HEK293T cells were transfected for 24 h using an equal weight of plasmid DNA and PEI-
MAX (Polysciences, Warrington, PA).  
The cells for qualitative Western blot analysis were transfected with receptor plasmids 
(1.6 µg DNA/well in a 6-well plate for a single type of receptor expression, and 0.8 µg 
DNA/well in a 6-well plate for any two receptors expressed simultaneously) or with the 
pUC19 plasmid (to 3.0 µg total DNA/well in a 6-well plate; Figure 5, 6, and 7).  
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For quantitative CISH reporter assay analyses, 50 ng of the pGL4-CISH plasmid, 5 ng of 
the TK-Renilla plasmid, and 12.5 or 25 ng of the PRLR non-variant with or without the 
variant plasmids (R171Ter, P269L, or H212R) were used to transfect HEK293T cells in 
a 24-well plate format. The total amount of DNA was adjusted using pUC19 to 755 
ng/well in 24-well plates (Fig. 8A and B). 
Confocal imaging 
HEK293T cells were cultured on coverslips in a 6-well plate. These cells were transfected 
with non-variant or variant plasmids (1.6 µg/well) by adding 1.4 µg of pUC19, followed 
by incubation for 24 h. Subsequently, the cells were fixed on each coverslip with 4% 
paraformaldehyde for 20 min followed by incubation in Super Block solution (Thermo 
Fisher Scientific) at room temperature for 30 min. The cells were incubated with anti-
human PRLR antibody (cat. GTX50723, Gene Tex, Irvine, CA, USA; 1:500) at 4°C 
overnight, rinsed twice with phosphate-buffered saline (PBS), and incubated with PBS 
containing anti-rabbit IgG antibody conjugated with Cy3 (Sigma-Aldrich, St Louis, MO, 
USA) and 1µg/ml of DAPI at room temperature for 30 min. Confocal scanning 
microscope (FV-10, Olympus, Tokyo, Japan) was used for imaging. 
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Western blotting 
Transfected HEK293T cells carrying the non-variant, R171Ter or P269L variants were 
stimulated with or without 100 ng/ml human recombinant prolactin (Wako, Osaka, Japan) 
for 30 min. The cells were then lysed using complete Lysis-M reagent (Roche, Basel, 
Switzerland) containing HaltTM Phosphatase Inhibitors Cocktail (Thermo Fisher 
Scientific) for 15 min and centrifuged the mixture at 15,000 × g for 15 min at 4°C. To 
separate supernatants, 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
was performed, and the proteins were transferred to a polyvinylidene difluoride 
membrane (Millipore, Burlington, VT, USA). After a pre-incubation with Blocking One-
P (Nacalai Tesque, Kyoto, Japan) or PBST containing 2% skim milk at room temperature 
for 30 min, the membranes were incubated with anti-phosphate STAT5 (pY694) antibody 
(Cat. 611965, BD, Franklin Lakes, NJ, USA; 1:1000), anti-STAT5 antibody (#25656, Cell 
Signaling Technology, Danvers, MA, USA; 1:1000), anti-PRLR antibody (Gene Tex, 
Irvine, CA, USA; 1:1000), or anti β actin antibody (#4967S, Cell Signaling Technology, 
1:5000) in PBST or in signal enhancer HIKARI (Nacalai Tesque) at 4°C overnight. After 
being washed in PBST, the membranes were incubated using anti-mouse or rabbit IgG 
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secondary antibodies (GE Healthcare, Boston, MA, USA; 1:10000 or 1:5000) at room 
temperature for 1 h. Finally, we detected and recorded the signals using ECL select or 
ECL Prime reagent (GE Healthcare). 
CISH promoter assay 
A promoter sequence of the cytokine-inducible SH2-containing protein9 [CISH; '1034 
to +1 at the ATG site; Assembly released Dec. 2013 (GRCh38/hg38), chr3:50611772–
50612806] was amplified using PCR and subcloned into the pGL4.10 plasmid (Promega) 
using the In-Fusion HD Cloning kit (Takara) and specific primers (Supplementary Table 
S1). We confirmed the fidelity of the clone by sequencing. 
After the transfections, the cells were incubated in serum-free DMEM GlutaMAX 
containing 0.5% bovine serum albumin without antibiotics. Then, after 24 h, the cells 
were stimulated using 10, 100, or 1000 ng/ml human recombinant prolactin for 24 h, 
washed with PBS once and lysed in 100 µl of Passive Lysis Buffer (Promega) at room 
temperature for 15 min. Subsequently, a luciferase assay was performed using the Dual-
Luciferase reporter assay system (Promega) and the Infinite-M200 (Tecan Japan, 
Kanagawa, Japan). Each transfection was performed in duplicate, and the experiments 
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were repeated three times. The values for Renilla luciferase activity were used to 
normalize the firefly luciferase activity and were expressed as fold inductions over the 
prolactin-untreated control samples. 
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Results  
The proband was a compound heterozygote of two cytosine-to-thymine transitions: one 
in exon 6 (NM_000949.6:c.511C>T; GenBank accession number: MH175194) and the 
other in exon 9 (NM_000949.6:c.806C>T; GenBank accession number: MH175193) of 
PRLR, predicting nonsense (R171Ter) and missense (P269L) changes at the amino-acid 
level, respectively (Fig. 9A and B). R171Ter has not been previously reported. P269L has 
been reported as a single nucleotide variant (rs754974807) with a minor allele frequency 
of 0.0000210; however, clinical significance of this variant has not been previously 
assessed. 
The proband’s mother and father were heterozygous for R171Ter and P269L, respectively. 
The proband’s sister and brother had neither variant. 
The 511C>T (R171Ter) variant gave rise to a premature termination codon, resulting in a 
short polypeptide comprising the N-terminal of an extracellular domain (Fig. 10). The 
predicted peptide lacks a transmembrane domain and the intracellular domain required 
for intracellular signal transduction, correct folding, and cellular trafficking, but has two 
disulfide-linked cysteines, which are predicted to confer on the peptide the ability to bind 
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ligand. It is predicted to be similar to the soluble prolactin-binding isoform comprising 
only an extracellular domain, which modulates the function of the full-length prolactin 
receptor1,11. We transfected HEK293T cells with a R171Ter PRLR containing plasmid to 
examine the function of the variant receptor. We detected it in the cytoplasm at a 
significantly lower level than that of the non-variant receptors (Fig. 11); we observed no 
signal in the cell membrane. We observed protein of the expected size protein albeit at 
lower levels than the non-variant receptor, using Western blotting (Fig. 5). The R171Ter 
mutant did not induce STAT5 phosphorylation in response to prolactin (Fig. 6).  
The 806C>T variant predicts a full-length protein with an amino-acid substitution 
(P269L) at the docking site for the protein Jack2 (Box 1), which is in phylogenetically-
conserved proline-rich domain (Fig. 12).12 We detected the variant protein in both the 
cytoplasm and cell membrane (Fig. 11). Assay by Western blotting showed an elevated 
level of expression (Fig. 5) and an inability to phosphorylate STAT5 (Fig. 6) compared 
with that of the non-variant prolactin receptor.  
We queried interactions between variant and non-variant prolactin receptors through co-
transfection experiments. Neither R171Ter- nor P269L-variant proteins suppressed 
 16 
STAT5 phosphorylation by the non-variant receptor when equimolar amounts of plasmids 
were transfected (Fig. 7). As expected, the co-expression of R171Ter- and P269L-variant 
prolactin receptors did not induce STAT5 phosphorylation in response to prolactin. 
The response to prolactin was quantified via the CISH promoter assay. The R171Ter-
variant prolactin receptor did not respond to prolactin, whereas the P269L-variant 
prolactin receptor responded in blunted fashion to 100–1,000 ng/mL of prolactin (Fig. 
8A). This small increase mediated by P269L PRLR-containing plasmid was suppressed 
by replacing half amount of this plasmid with an equimolar amount of R171Ter PRLR-
containing plasmid, to create a condition mimicking that in a compound heterozygote 
(Fig. 8A). We also evaluated the possibility that the variants had a dominant-negative 
effect on the non-variant receptor. The P269L variant attenuated the response of the non-
variant receptor by approximately 20%, whereas the R171Ter and H212R variants 
showed limited attenuation (Fig. 8B).  
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Discussion 
Here we describe a woman with compound heterozygous germline inactivating variants 
of PRLR and hyperprolactinemia associated with postpartum lactation failure. 
Biochemical data indicate that the variants negatively impact the prolactin receptor 
signaling pathway. Although we report the results of a single patient who may have other 
genetic variants (other than those in PRLR) that impact lactation, our data are also 
consistent with the notion that transduction via the prolactin receptor is essential for 
lactation in humans. 
Our data are consistent with possibility that reduced lactation during breast-feeding is 
caused by heterozygous loss-of-function variants. The proband’s mother, who was 
heterozygous for the R171Ter variant and she reportedly experienced “insufficient” 
lactation. Similarly, mice heterozygous for a Prlr null allele have shown diminished 
lactation. That being said, we cannot exclude the possibility that insufficient lactation by 
the proband’s mother was a coincidental symptom and unrelated to allelic status of PRLR. 
Our data support that loss of prolactin receptor signaling does not disturb fertility in 
humans. The proband’s parents, heterozygotes, were fertile. The proband, a compound 
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heterozygote, showed normal gonadotropin secretion, had a normal menstrual cycle and 
was fertile, although the first pregnancy was achieved through intrauterine insemination 
after a year of trying to conceive without medical assistance. Thus, biallelic loss of 
function of PRLR would not seem to cause infertility in humans, although it is possible 
that there was some residual function of the P269L variant; ie, it is possible that the 
proband was not completely null for PRLR function, and that residual function was key 
to her being able to conceive. Female mice homozygous for null mutations affecting 
prolactin receptor signaling have multiple reproductive defects, including infertility13,14. 
Excessive production of prolactin inhibits the secretion of gonadotropin and leads to 
anovulation, probably by suppressing kisspeptin-1 release from the kisspeptin-1 neurons 
that express the prolactin receptor in the hypothalami of mice and humans15. The proband 
had loss of signaling by the prolactin receptor and yet had normal gonadotropin secretion, 
a finding consistent with the previous observation that a deficit of prolactin seems to have 
no effect on gonadotrophin secretion.  
The inheritance pattern in the proband’s family corresponds to an autosomal recessive 
trait, suggesting haplosufficiency of PRLR (ie, having one fully functional allele of PRLR 
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is sufficient to support lactation). Our biochemical data showed that both pathogenic 
variants imposed a loss of function on the receptor but did not exert robust dominant-
negative effect on the non-variant receptor. Both variants together led to profound loss of 
signal transduction. These data support our conclusion that biallelic loss-of-function 
variants in PRLR is the cause of the lactation phenotype in this case. 
A short-loop, negative-feedback regulatory mechanism of prolactin on its own secretion 
has been demonstrated using Prlr knock-out mice16. Pituitary lactotrophs secrete 
prolactin that binds to the prolactin receptor of tuberoinfundibular dopaminergic neurons 
which then produce dopamine. The released dopamine sequentially acts on pituitary 
lactotrophs and inhibits prolactin secretion17. Our data support the presence of this short-
loop feedback regulation in humans16. Both the mouse and the human also demonstrate 
haplosufficiency of PRLR; ie, a single functional copy of PRLR or (in the case of mouse) 
Prlr allele18,19 is sufficient to maintain basal levels of serum prolactin within the normal 
range.  
In a previous report3 heterozygotes carrying a loss-of-function variant (H212R) in PRLR 
displayed paradoxical symptoms (hyperprolactinemia and persistent postpartum 
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galactorrhea). We found that the three variant receptors (R171Ter, P269L, and H212R) 
were almost similar in terms of residual signal transduction function and the absence of 
robust dominant-negative effect. Perhaps other factors that modulate prolactin receptor 
signaling explain the difference in phenotype between the two families.2 Relevant to this 
hypothesis is the high level of variation in the relationship between serum prolactin levels 
and galactorrhea among women.20 The results of our study of a woman with compound 
heterozygote of loss-of-function mutations in PRLR and lactation failure associated with 
hyperprolactinemia would suggest that only lactation (and not other biological functions) 
is dependent on prolactin-PRLR signaling, although further study is required to test this 
hypothesis. 
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Figure legends 
 
Figure 1. Pedigree of the family with PRLR genotypes identified by bi-directional 
sequencing. 
 
Figure 2. Chest X-ray. This image was taken at 36 weeks of the first pregnancy as 
preoperative screening for cesarean section. 
 
Figure 3. Serum levels of prolactin and thyroid-stimulating hormone after loading 500 µg 
of thyroid hormone-releasing hormone. PRL, prolactin; TSH, thyroid-stimulating 
hormone. 
 
Figure 4. MRI performed on the initial hospital visit.  
T2 TSE: T2-weighted turbo spin echo; T1 SE: T1-weighed spin echo. 
 
Figure 5. Western blot of non-variant and variant receptors expressed by HEK293T cells. 
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24 hours after transfection, HEK293T cells were lysed and blotted using anti-PRLR 
antibody. 
 
Figure 6. Western blot analysis to detect STAT5 phosphorylation in HEK293T cells on 
exposure to prolactin. HEK293T cells were incubated with prolactin (100 ng/ml) for 30 
minutes, 24 hours after transfection with non-variant, R171Ter, or P269L type plasmids 
(1.6 µg DNA/well on a 6 well plate). 
 
Figure 7. Western blot analysis to detect functional interactions based on STAT5 
phosphorylation status after exposure to prolactin by HEK293T cells expressing different 
types of PRLR. 
 
Figure 8. A; Dose-response curve of the cytokine-inducible SRC homolog 2 domain 
protein (CISH) luciferase reporter gene in HEK293T cells transfected plasmids carrying 
non-variant or variant PRLR and a green fluorescent protein gene. B; CISH assay to query 
effect of variant receptor on function of non-variant receptor. For comparison, H212R, a 
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previously reported variant of PRLR, was included. Error bars represent standard 
deviations.  
 
Figure 9. Chromatograms obtained by direct sequencing of PCR products. 
 
Figure 10. Schematic representation of the PRLR, full-length cDNA, and protein-domain 
structure. Variants and predicted effect on protein are also depicted. 
 
Figure 11. Expression of the prolactin receptor (PRLR). Human embryonic kidney (HEK) 
293T cells were transiently transfected with vector carrying non-variant or variant PRLR 
sequences and GFP, encoding green fluorescent protein. Confocal imaging detected the 
green fluorescent protein (GFP) (top) and Cy3 (middle) signals. Bottom: superimposition 
of GFP, Cy3, and 4',6-diamidino-2-phenylindole (DAPI) stain. 
 
Figure 12. Alignment of PRLR sequence across species. Conserved sequence is indicated 
by yellow background; the P269Lvariant is highlighted in blue. 
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Table 1 Serum
 lipid levels 
A
ge 
30 years 6 m
onths 
30 years 11 m
onths 
31 years 4 m
onths 
31 years 11 m
onths 
35 years 10 m
onths 
 
non-pregnant 
non-pregnant 
non-pregnant 
20 w
eeks of pregnancy 
non-pregnant 
TG
 (m
g/dL) 
82 
47 
70 
137 
88 
LD
L (m
g/dL) 
120 
145 
132 
191 
193 
H
D
L (m
g/dL) 
81 
58 
73 
85 
79 
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Table 2 Prim
er sequences and Tm
 used for PCR am
plification, sequencing, m
utagenesis, and subcloning 
U
se 
Target 
Forw
ard Prim
er 
Reverse Prim
er 
A
nnealing 
tem
perature for PCR  
PCR Product 
size (bp) 
Sequencing 
Exon 1 of PRLR 
CTAAAACTGGCAGGCTCTGG  
CGCTCTCCCCTTCAGCAC 
60 
462 
Exon 2 of PRLR 
TCAGCCATGCTACGTACTGC  
GAGGGGCATGAGAACAAGTC 
60 
179 
Exon 3 of PRLR 
CTGACCAGACTGCCATTTCA  
TGCAAGAAGACTGCATGGAC 
60 
243 
Exon 4 of PRLR 
CAGTGGCTTCTGGCTTTTTC 
GGGATGTGCTGTCACTCAGA  
60 
248 
Exon 5 of PRLR 
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